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ABSTRACT
Bronchopulmonary dysplasia (BPD), also known 
as chronic lung disease of prematurity, is the 
major cause of pulmonary disease in infants. 
The pathophysiology and management of BPD 
have evolved over the past four decades as 
improved neonatal intensive care unit (NICU) 
modalities have increased survival rates. The 
likelihood for developing BPD increases with the 
degree of prematurity and reaches 25–35% in 
very low-birth-weight and extremely low-birth-
weight infants. BPD affects many organ systems, 
and infants with BPD are at increased risk for 
rehospitalization and numerous complications 
following NICU discharge. The management of 
BPD and medically related problems, particularly 
during the first 2 years of life, remains a 
continuing challenge for parents and healthcare 
providers. It is important that a multidisciplinary 
team consisting of the neonatologist/attending 
physician, primary care physician, and other 
specialized support staff work in concert and 
meet regularly to provide continuity of care and 
accurate patient assessments.
Keywords: Bronchopulmonary dysplasia; Chronic 
lung disease of prematurity; Complications; 
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INTRODUCTION
The Origins of Bronchopulmonary Dysplasia
Bronchopulmonary dysplasia (BPD), also known 
as chronic lung disease of prematurity, is the 
most common pulmonary complication of very 
preterm birth [1–3]. The likelihood of developing 
BPD is directly associated with preterm 
infants with a very low-birth-weight (VLBW), 
defined as infants born weighing < 1500 g, 
and extremely low-birth-weight (ELBW), defined 
as infants born weighing < 1000 g, who were 
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changes, clinical presentation, and nomenclature 
(i.e., from “old” BPD to “new” BPD) [5–7]. This 
paper reviews outpatient management of some of 
the most common medical issues associated with 
BPD. These include promoting optimal growth 
and nutrition, gastroesophageal reflux and 
constipation, current immunization practices, 
prevention of viral respiratory infections, 
neurodevelopment, and management of chronic 
lung disease, including home oxygen therapy.
“Old” Versus “New” Bronchopulmonary 
Dysplasia
A workshop jointly organized by the National 
Institute of Child Health and Human 
Development and the National Heart, Lung, 
and Blood Institute convened in 2000 to further 
refine the definition of BPD and discuss the 
state of knowledge regarding BPD-induced 
lung injury, treatment interventions, and areas 
initially treated for respiratory distress syndrome 
[1]. The first description of BPD was in 1967 
when Northway and associates published 
their landmark study regarding the clinical, 
radiologic, and pathologic changes observed 
in 32 neonates born after approximately 
32 weeks’ gestation with severe respiratory 
distress syndrome who were treated with 
prolonged artificial ventilation and high 
concentrations of oxygen [4]. Northway and 
associates coined the term, “bronchopulmonary 
dysplasia,” to describe a syndrome of chronic 
lung disease that comprised four stages of 
progressive pulmonary sequelae, the latter 
of which extended beyond 1 month. Given 
improvements in neonatal care and higher 
survival rates among neonates of low birth weight 
since Northway’s original observations nearly 
45 years ago, the definition of BPD has undergone 
several iterations with respect to pathology, 
need for supplemental oxygen, radiographic 
Table 1  Definition of BPD: diagnostic criteria.a Reprinted with permission of the American Thoracic Society. Copyright © 2012 
American Thoracic Society. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Care Med. 2001;163:1723–9
Gestational age
< 32 weeks ≥ 32 weeks
Time of assessment 36 weeks postmenstrual age or discharge to 
home, whichever comes first
< 56 days postnatal age or discharge to home, 
whichever comes first
Mild BPD Breathing room air at 36 weeks 
postmenstrual age or discharge, whichever 
comes first
Breathing room air by 56 days postnatal age 
or discharge, whichever comes first
Moderate BPD Need for < 30% oxygen at 36 weeks 
postmenstrual age or discharge, whichever 
comes first
Need for < 30% oxygen at 56 days postnatal 
age or discharge, whichever comes first
Severe BPD Need for ≥ 30% oxygen and/or positive 
pressure (PPV or nCPAP) at 36 weeks 
postmenstrual age or discharge, whichever 
comes first
Need for ≥ 30% oxygen and/or (PPV 
or nCPAP) at 56 days postnatal age or 
discharge, whichever comes first
a Maintain pulse oximetry saturation ≥ 92–95% 
BPD bronchopulmonary dysplasia, nCPAP nasal continuous positive airway pressure treatment, PPV positive pressure 
ventilation
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(i.e., saccular stage), and from 32–36 weeks to 
term and beyond to 2 years of age (i.e., alveolar 
stage), and are characterized by alveolar and 
capillary development, respectively. The 
clinical profile of “new” BPD has shifted to 
a younger ELBW gestational age grouping of 
infants who have not reached term-equivalent 
development by 1 month of age [7, 8]. Whereas 
the main features of “old” BPD include 
profound inflammation, nonhomogeneous 
airway, and parenchymal disease, “new” 
BPD is characterized by decreased alveolar 
development and milder pathologic changes 
(Table 2) [8].
Risk Factors for Bronchopulmonary 
Dysplasia
Numerous factors have been associated with an 
increased risk for the development of BPD in 
susceptible neonates. With rare exceptions, BPD 
is preceded by the use of mechanical ventilation 
early in life [7]. Although VLBW/ELBW infants 
may not initially require ventilator assistance, 
it is often instituted because their extremely 
premature lung function and overly compliant 
chest wall usually results in CO2 retention, 
for future research [7]. In contrast to earlier 
definitions that lacked specificity, a new, more 
tailored definition of BPD was proposed that 
incorporated disease severity rankings assessed 
at identified time points in infants less than 
or greater than 32 weeks gestational age who 
required oxygen treatment for at least 28 days 
(Table 1) [7]. Excluded from the “new” definition 
were references to chest radiograph findings due 
to their subjective nature of interpretation and 
frequent lack of availability. Also excluded from 
the new diagnostic criteria were mentions of 
the clinical features of disease (e.g., tachypnea, 
retractions, and rales) as they are considered 
common to the overall description of BPD [7].
The epidemiology of BPD has changed 
considerably over the past four decades as 
the availability of surfactants, administration 
of antenatal corticosteroids, and improved 
ventilation techniques have reduced the 
incidence of severe lung injury in the more 
mature and heavier birth-weight neonate 
cohort [1, 7, 8]. The human lung undergoes 
maturation during five stages, each of which 
has distinct growth milestones at specific 
gestational periods [9]. The latter two stages 
extend from 26–28 to 32–36 weeks gestation 
Table 2  Pathologic characteristics of “old” versus “new” BPD [8]
Old BPD Altered inflation pattern: atelectasis and overinflation
Severe airway epithelial lesions (hyperplasia, squamous metaplasia)
Airway smooth muscle hyperplasia
Extensive fibroproliferation
Prominent vascular hypertensive lesions
Decreased internal surface area and alveoli
New BPD Decreased, large, and simplified alveoli (alveolar hypoplasia, decreased acinar complexity)
Decreased, dysmorphic capillaries
Variable interstitial fibroproliferation
Less severe arterial/arteriolar vascular lesions
Negligible airway epithelial lesions
Variable airway smooth muscle hyperplasia
BPD bronchopulmonary dysplasia
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apnea, weak inspiratory effort, pulmonary 
edema from patent ductus arteriosus, 
pneumonia, and/or respiratory distress. 
Women at risk of very preterm birth often have 
asymptomatic histologic chorioamnionitis 
and low-grade infection [10]. It has been 
hypothesized that antenatal endotoxin may 
compromise fetal lung development and prime 
the neonate for BPD following the introduction 
of further insults (e.g., mechanical ventilation, 
sepsis) [10, 11]. Other factors widely associated 
with the development of BPD include genetic 
susceptibility, extremely premature birth and 
VLBW, prolonged mechanical ventilation and 
oxygen administration, persistence of patent 
ductus arteriosus, vascular maldevelopment, and 
postnatal fluid overload [7, 12–15].
Incidence of Bronchopulmonary Dysplasia
The reported incidence of BPD has varied 
from one study to another, most likely as a 
result of differences in clinical definitions [16], 
demographics of patient populations, and 
management strategies used across studies [17]. 
These differences aside, the incidence of BPD 
is established to be inversely proportional to 
birth weight and gestational age [17]. A recent 
prospective trial conducted from October 2000–
June 2002 by researchers at the National Institute 
of Child Health and Human Development 
Neonatal Research Network reported an overall 
incidence of BPD of 25–35% (depending on 
definition for BPD used to calculate incidence) 
among infants with a birth weight of 501–1,249 g 
[16]. The severity of BPD decreased as gestational 
age increased. These results were similar to the 
national incidence of BPD in 2002 of 33.7%, 
as analyzed from hospitalization records in the 
Nationwide Inpatient Sample [18]. Although 
the American Lung Association indicates that 
there are between 5,000 and 10,000 new cases 
of BPD each year in the USA. This is likely an 
underestimation of the true incidence given the 
National Vital Statistics birth data of 4.2 million 
new births in the USA in 2008, of which 1.46% 
consisted of ELBW infants [19] and the estimated 
percentage of VLBW/ELBW infants who develop 
BPD (i.e., 20–35%).
DISCHARGE PLANNING
Although survival rates for VLBW/ELBW children 
have significantly increased since BPD was first 
described, many of these infants face future 
problems with respect to neurodevelopmental 
outcomes and growth impairment [20]. In 
addition to higher rates of morbidity than full-
term infants, VLBW/ELBW preterm infants 
experience an increased incidence of hospital 
readmission, especially during the first 2 years 
of life, which is more than twice that reported 
for preterm children without BPD [21–25]. These 
children also have greater need for outpatient 
services in early childhood [26]. These issues are 
further accentuated in VLBW/ELBW children 
with BPD. With these challenges in mind, 
discharge planning needs to begin well before 
the infant leaves the hospital and appropriate 
outpatient management strategies implemented 
to prevent or mitigate future health and 
development issues.
The discharge planning team typically 
consists of the treating neonatologist/pulmonary 
specialist; neonatal nurses; therapists with 
specialized expertise in nutrition, respiratory, 
and home healthcare; social workers; other 
professionals as needed; and infant’s parents 
or primary caregiver. Certain elements are 
standard to any discharge program and take into 
consideration the physiologic status of the infant, 
treatment plans, tracking programs, and ability 
of the guardian to care for the child at home 
(Table 3) [27–31]. Before discharge, it is essential 
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Table 3  Discharge planning and home management programs [27, 29–31]
Physiologic stability No acute respiratory exacerbations
Oxygen requirement stable with no significant desaturations
No clinically significant apnea/bradycardia
Steady weight gain (20–30 g/day) on a simple feeding plan
Medication schedule stable and reasonable for home use
Active program of parental 
involvement and preparation  
for care of the infant at home
Caregiver identified, adequate financial resources and health insurance in place, home care 
education and home assessment initiated well before discharge
Caregivers should:
Be trained in assessment of clinical status, including home oxygen management. They need 
to display skills in observation of signs of respiratory deterioration, such as hypoxia, pallor, 
cyanosis, lethargy, irritability, tachycardia, tachypnea, and poor feeding
Be aware that oxygen needs may increase with illness, poor weight gain, etc.
Be trained in CPR and emergency intervention, operation of any specialized equipment, 
basic infant care, and administration of any required medications
Have adequate housing, access to telephone and transportation, emergency contact 
numbers identified, home oxygen, and other preterm issues in place
Arrangements for healthcare 
after discharge by a physician or 
other healthcare professional and 
identification of support services
Identification of a primary care physician and coordination of care with treating 
neonatologist/specialist
Multidisciplinary team approach to include nursing visits for infant assessments, social 
workers, nutritionists, physical therapists, speech therapists, and occupational therapists
Organized program of tracking 
and surveillance to monitor 
growth and development, and 
timeline of pediatric care
Plotting of weight to height ratios
Neurodevelopment follow-up for evidence of motor and cognitive developmental 
abnormalities, speech and language delay
Monitoring for retinopathy of prematurity and hearing disorders
Infancy–4 months Examine for strabismus, assess growth and nutrition monthly, evaluate family stress and 
parent–infant interaction
4–6 months Assess growth and nutrition monthly, refer for standardized movement assessment and assessment 
of muscle tone and movement quality, evaluate family stress and parent-infant interaction
8–12 months Assess growth and nutrition monthly, refer for standardized movement assessment and 
assessment of muscle tone and movement quality, refer to ophthalmologist for vision 
assessment, screen language, fine motor–adaptive and personal–social skills, evaluate 
family stress and parent–infant interaction
15–18 months Assess growth and nutrition at 3-month intervals, assess family support at 3-month 
intervals, refer for standardized movement assessment, screen other areas of development 
and social interaction
2–5 years Yearly neurodevelopment examination, continued medical supervision and coordination 
of patient care, psychosocial support, introduction to preschool experience
5–18 years Ongoing developmental assessments, educational testing, continued medical supervision, 
psychosocial support, counseling about health dangers of smoking
CPR cardiopulmonary resuscitation
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that the infant shows evidence of clinical stability 
and is able to accept oral feedings, maintain 
normal body temperature, and have sufficiently 
mature respiratory control. These functions are 
usually achieved by a corrected gestational age 
at or near term (> 36 weeks corrected) [32, 33], 
but related problems may persist for a longer 
period [34]. The infant should be examined for 
retinopathy of prematurity (ROP), undergo a 
hearing evaluation and metabolic screen review, 
and be given appropriate immunizations. 
Physiologic competencies should be assessed 
on an individual basis as they are influenced 
by birth weight, gestational age, and medical 
course. Consequently, predicting the time to 
hospital discharge for extremely preterm infants 
is difficult [35] and responsibility for the final 
decision regarding discharge rests with the 
attending physician [27].
It is essential that appropriate caregivers are 
identified and properly trained in issues relevant 
to care of the infant (Table 3) well in advance of 
neonatal intensive care unit (NICU) discharge. 
The caregivers must be aware that the infant 
will have special needs beyond those of term 
infants and should be able to recognize signs and 
symptoms of respiratory distress, poor feeding 
habits, and other relevant health problems 
before bringing these infants home. A balance 
needs to be achieved so that caregivers do not 
become overprotective to the point that they 
consider their child to be excessively vulnerable 
and limit their activities to explore and play with 
other children in an interactive environment 
that promotes normal psychosocial development 
[1]. Caring for a VLBW/ELBW infant with BPD 
presents unique challenges that can increase stress 
levels and promote anxiety and/or depression in 
those with poor coping skills [36, 37]. Appropriate 
family support systems should be identified 
and behavioral interventions implemented to 
mitigate any psychologic problems that arise [38].
After discharge, it is important that a 
multidisciplinary team, consisting of the 
neonatologist/attending physician, primary 
physician, and other specialized support staff, 
work in concert and meet regularly to provide 
a continuum of care and accurate patient 
assessments. The first follow-up visit should 
ideally be scheduled within 1–2 weeks after 
discharge with subsequent visits guided by the 
clinical status of the infant [28]. Activities and 
assessments to be monitored at prescheduled 
dates are included in Table 3.
Related Medical Problems
BPD is a disease that affects many major organ 
systems, including the heart, lungs, central 
nervous system, gastrointestinal tract, and 
kidneys. Infants and young children with 
BPD are at increased risk of rehospitalization 
and numerous complications during home 
management (Table 4) [1, 30]. The risk of poor 
outcomes, including death, in VLBW/ELBW 
infants is greatest for those with severe BPD, 
brain injury, and severe ROP [39]. The incidence 
of medically related problems is usually greatest 
during the first 2 years after discharge but can 
persist beyond very early childhood [40].
Results from early studies on the long-term 
effects of “old” BPD on pulmonary function 
suggested that infants with severe BPD could 
remain symptomatic and exhibit evidence of 
airway obstruction as adults [41]. Initial results 
from more recent studies in children with “new” 
BPD appear to be somewhat similar to previous 
findings and indicate that these children have 
a continuum of poor respiratory health that 
extends out to at least 8 years of age [42, 43]. 
However, longer-term pulmonary effects of 
“new” BPD remain to be fully studied. Impaired 
neurodevelopment in children with BPD, as 
manifested by difficulties with gross and fine 
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motor skills, impaired visuomotor integration, 
and comparatively lower intelligence quotient 
(IQ) scores and school performance than 
controls, is common and thought to result 
from multiple insults, including prolonged 
hypoxemia [44]. Careful attention should be 
given to results of standardized comprehensive 
testing conducted when the child enters school, 
as the most significant neurodevelopment issues 
secondary to BPD may first become evident at 
this time [30]. Other potential medically related 
issues in children with BPD include impaired 
growth and diminished fat stores [45]; respiratory 
infection, especially with respiratory syncytial 
virus (RSV) [46]; gastroesophageal reflux, 
which is influenced by feeding intolerance and 
prolonged gastric tube use [47]; sensorineural 
and/or conductive hearing loss [48]; and ROP.
OUTPATIENT MANAGEMENT
Growth and Nutrition
Failure to thrive is common among infants 
with BPD [17, 31] due to increased rates of 
energy expenditure, and increased nutrient and 
caloric requirements. Oral aversion, feeding 
intolerance, and/or gastroesophageal reflux all 
Table 4  Potential medically related issues/complications of BPD after hospital discharge [1]. Adapted with permission from 
Vaucher YE. Bronchopulmonary dysplasia: an enduring challenge. Pediatr Rev. 2002;23:349–58P










Glottic and subglottic damage
Tracheal and bronchial stenosis, tracheobronchomalacia
Acute life-threatening event
Sudden infant death syndrome
Neurologic system and 
development
Impaired motor and cognitive function
Impaired social responsiveness to animate and inanimate stimulation
Feeding, nutrition, and 
gastrointestinal system
Slow weight gain and failure to thrive
Vitamin and mineral deficiencies
Feeding intolerance
Gastroesophageal reflux
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make feeding difficult. Poor weight gain may 
also be a sign of unsuspected hypoxia, especially 
at night when oxygen saturations fall during 
sleep. Consequently, infants with BPD do not 
always achieve reference growth during their 
first year despite nutrition plans that include 
protein and energy intake comparable with those 
recommended for healthy term infants [49]. 
During early childhood, VLBW/ELBW 
children continue to be smaller and lighter 
than their normal weight counterparts, with 
catch-up growth usually occurring between 
8 and 14 years of age. As such, growth 
monitoring is an integral part of the medical and 
nutritional assessment of these infants because 
of the effect of poor nutrition on the developing 
brain [50] and potential cognitive, neurologic, 
and neurosensory morbidity [51].
The goal should be to attain comparable growth 
velocities and percentiles for corrected age as with 
those for term infants [17]. At 40 weeks corrected 
age, growth assessments for infants with BPD 
should be plotted on standard charts that take into 
consideration length, weight, length/weight ratio, 
and head circumference. These should be plotted 
using the infant’s corrected age. Each of these 
measurements has a prognostic ability for assessing 
appropriate growth. Optimal weight gain targets 
are 20–30 g/day with emphasis on the rate of 
weight gain. Small head circumference at 1 year is 
linked with low cognition and learning disabilities 
at school age [52]. Head circumference should fall 
within 1 SD for corrected age and infants with head 
circumference that is ≥ 2 SD less than the mean 
should be closely watched for developmental 
delays. Optimal growth targets are 0.7–1.1 cm/week 
for linear growth and 0.4–0.6 cm/week for head 
circumference growth. Infants who are not on a 
growth trajectory that is at least parallel to standard 
curves deserve further evaluation.
The basic caloric and protein requirements of 
the infant with BPD frequently exceed those of the 
term neonate. Caloric and protein intake in VLBW/
ELBW infants may need to be increased because of 
the higher metabolic needs. Caloric and protein 
supplementation presents unique challenges, 
and postdischarge nutrient requirements for the 
preterm infant are constantly undergoing revision. 
Current recommendations are designed to provide 
nutrition to approximate the rate of growth 
and weight gain for a normal fetus of the same 
postmenstrual age [53]. Standard formula may be 
carefully fortified up to as high as 27 cal/30 mL by 
following guidelines, such as those provided by the 
Children’s Hospitals and Clinics of Minnesota [54]. 
Currently available specialized premature formulas 
(3.0 g per 100 kcal) and postdischarge formulas 
(2.8 g per 100 kcal) contain significantly more 
protein than the standard formula. A study in 
18 healthy VLBW infants compared the effects of 
giving isocaloric formulas containing either 3.6 g 
of protein per 100 kcal versus the standard 3.0 g 
per 100 kcal. In both formulas, the protein was 
provided as fully hydrolyzed bovine whey protein. 
The high-protein group showed greater nitrogen 
balance and weight gain without any evidence of 
uremia or metabolic acidosis [55, 56].
Breast milk feeding has been encouraged for 
VLBW/ELBW infants as it may help prevent 
future cognitive problems and offers other 
health benefits. If the mother breast feeds, 
individualized fortification of expressed milk 
may be required to ensure the infant receives 
much-needed nutrients and calories not 
contained in the milk. Preliminary data from a 
limited number of studies indicate that nutrient-
enriched mother’s milk improved cognitive 
development among very preterm infants [57], 
but significant effects on growth parameters were 
equivocal [58, 59]. Careful monitoring should 
be performed with the help of a professional 
experienced in this area.
Attention should also be given to the vitamin, 
folate, mineral, iron, and trace element needs 
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of the infant and appropriate supplementation 
provided. In addition to correcting any deficits, 
vitamin and mineral supplementation may also 
aid in recovery from BPD [17]. VLBW/ELBW 
infants are at high risk of anemia because they 
have low iron stores, which are depleted quickly. 
Elemental iron supplementation should start 
early on (usually between 4 and 8 weeks) at a 
dose of 2–4 mg/kg per day and continued for 
12–15 months [60]. However, additional iron 
supplementation (up to 6 mg/kg per day) may 
be required for some VLBW/ELBW children.
Gastroesophageal Reflux and Constipation
Reflux is a common disorder in the VLBW/
ELBW infant with BPD [61]. Symptoms of 
severe reflux may include feeding aversion, 
failure to thrive, or worsening of chronic 
lung disease. Mild reflux may be treated 
by thickening feedings with rice cereal, 
maintaining the infant in a 30° prone position 
(with observation) for approximately an hour 
after feeds, and use of a pacifier. Medication 
and occasionally surgery may be required for 
severe gastroesophageal reflux. Constipation is 
very common in formula-fed infants due to a 
combination of factors, including high caloric 
formula feeds and insufficient fluid intake. 
For cases of severe refractory constipation, 
alternative causes should be sought, such 
as an undiagnosed stricture from previous 
necrotizing enterocolitis.
Immunization
The American Academy of Pediatrics notes that 
most preterm infants, including those with 
BPD, produce sufficient disease-preventable 
immunologic responses and are not at 
significantly increased risk for adverse events 
following full-dose vaccine administration [62]. 
Preterm infants should, therefore, receive the 
standard childhood vaccines consistent with 
their chronologic age. As all preterm infants 
are at increased risk for complications due 
to influenza, they should be administered 
influenza vaccine beginning at 6 months of 
age and according to recommendations and 
dosing schedules established by the Advisory 
Committee on Immunization Practices [63]. It 
is also recommended that all members of the 
household > 6 months of age be vaccinated 
against influenza [63].
Viral Respiratory Illness
In the USA, bronchiolitis secondary to RSV 
infection is the leading cause of hospitalization 
due to serious lower respiratory tract disease in 
infants and young children [64]. The combined 
presence of BPD and premature birth increases 
the likelihood of hospitalization due to RSV 
illness, especially in infants and children 
younger than 24 months [65]. A good plan to be 
practiced by caregivers to reduce the likelihood 
for infections includes meticulous hand washing; 
avoidance of large crowds, such as those 
present in shopping malls, daycare centers, and 
physician waiting rooms; and postponement 
of any infant elective surgeries until after the 
respiratory season. No vaccines against RSV are 
presently available, but a monoclonal antibody 
that affords passive immunity against serious 
lower respiratory tract RSV illness is available for 
specified high-risk populations [66].
Medications
The treatment of BPD can be categorized into 
three distinct stages that include prevention 
(stage 1, up to 7 days postnatal), treatment of 
evolving BPD (stage 2, beginning at 7–14 days of 
age), and treatment of established BPD (stage 3, 
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beginning at 28±7 days of age) [67]. Medications 
used during outpatient management of infants 
with BPD (i.e., stage 3) include corticosteroids, 
bronchodilators, and, rarely, diuretics [1, 67].
Systemic corticosteroids should be used with 
caution, particularly in the newborn period, as the 
benefit of reduced mortality needs to be weighed 
against the risks of serious short-term safety concerns 
and potential for neurodevelopmental impairment 
[68]. Inhaled corticosteroids are routinely used 
for treatment of asthma-like symptoms in these 
children, but few studies have documented 
their clinical effectiveness for routine outpatient 
management or improvement of BPD [1, 69]. 
Inhaled bronchodilators (i.e., beta2-agonists, 
anticholinergic agents) can improve short-term 
lung function by decreasing airways resistance in 
infants with BPD who have hyperactive airways. 
The etiology of wheezing in children with BPD is 
different from true asthma, and few studies have 
evaluated the efficacy of bronchodilators in patients 
with stable BPD beyond the neonatal period [70]. 
Routine administration of bronchodilators to 
stable outpatients with chronic lung disease is not 
warranted and should be reserved for children 
with clinical or functional evidence of reversible 
airways obstruction [2, 71]. The preferred method 
of bronchodilator delivery in this population is by 
metered-dose inhaler, with or without a spacer device 
and facemask, as it results in greater lung deposition 
than that achieved with nebulization [69]. 
Thiazide diuretics and spironolactone mobilize 
excess fluid and improve lung compliance acutely 
but their use in long-term outpatient management 
should be reserved for children with impaired 
cardiac function [1, 2, 71]. Pulmonary compliance, 
lung function, and hyperreactivity with wheezing 
usually improve over the first 2 years of life. 
However, overall reduced respiratory reserve may 
persist in a latent fashion and increase the risk of a 
chronic obstructive pulmonary disease-like illness 
later in life [2].
Home Oxygen Therapy
The goal of successful home oxygen therapy is 
to promote growth and repair of the developing 
lung, improve exercise tolerance, optimize 
cognitive development, and reduce the risk for 
pulmonary hypertension [1]. An added benefit 
of oxygen therapy may also be promotion of 
weight gain [72]. These positive effects are due 
to the ability of oxygen to reduce pulmonary 
artery pressure, acutely reverse functional hypoxic 
vasoconstriction, and decrease metabolism [1, 73]. 
Controversy still exists regarding the specific 
criteria for use of home oxygen therapy for 
infants with BPD despite over 20 years of use, as 
well as its impact on patient outcome. Results 
of a retrospective study of neonates born at a 
median gestational age of 27 weeks indicated 
that children with BPD who required home 
oxygen therapy after primary hospital discharge 
had increased respiratory morbidity and greater 
healthcare resource utilization during the first 
2–4 years of life than similarly matched children 
who did not require home oxygen therapy [74]. 
The home oxygen cohort experienced significantly 
more outpatient attendances, visits to specialists, 
prescriptions, and total healthcare costs than 
the comparator group, even though most were 
no longer dependent on oxygen use. A greater 
proportion of the home oxygen group experienced 
wheezing in general, more frequent wheezing 
than children with wheezing in the comparator 
group, and required inhaler therapy. Further trials 
are necessary to determine whether these findings 
are the results of a more severe disease among 
children who required home oxygen therapy. For a 
successful home oxygen program, careful selection 
and education of the family/caregivers and 
meticulous follow-up with the interdisciplinary 
healthcare team are essential [75]. Weaning from 
oxygen therapy is a slow process that involves close 
management to avoid potential complications, 
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and should only be attempted after the infant 
is clinically stable and shows signs of adequate 
weight gain [29]. One such weaning program 
is described in Table 5 [1, 17, 29]. Persistently 
low oxygen saturations resulting from too rapid 
oxygen reduction or discontinuation may result 
in poor sleeping and feeding, poor weight gain, 
and developmental delays [72, 73]. After the 
infant is completely weaned from oxygen therapy, 
monitoring of respiratory status and weight gain 
should continue for up to 6 months or more. To 
reduce concern, parents should be informed that 
reinstatement of oxygen support therapy may 
be necessary, especially during the winter season 
when viral respiratory infection is common [1, 29].
The American Thoracic Society currently 
recommends that infants with BPD who are 
past the age of oxygen-induced ROP should be 
supplemented with oxygen to maintain an oxygen 
saturation of ≥ 95%, including during feeding and 
sleep [1]. The Supplemental Therapeutic Oxygen 
for Prethreshold Retinopathy of Prematurity 
(STOP-ROP) and Benefits of Oxygen Saturation 
Targeting (BOOST) trials suggest that lower 
oxygen saturation targets may be of benefit, 
and may reduce the overall burden of home 
oxygen therapy [76, 77]. Halbower and McGrath 
accurately conclude that, “a consensus for the 
optimal oxygen saturation target in infants with 
chronic lung disease is essential. Future research 
efforts should emphasize oxygen saturation goals 
that optimize [growth and] development while 
simultaneously avoiding collateral damage to 
vulnerable organs” [78].
Neurodevelopment
BPD poses a significant risk for neurodevelopmental 
compromise. Postnatal infection and/or 
sepsis, periventricular leukomalacia, severe 
intraventricular hemorrhage, hearing impairment, 
and severe ROP are all important confounding 
variables that can greatly affect an infant’s 
neurodevelopmental outcome. The risk of 
neurodevelopmental impairment, cerebral palsy, 
and low IQ more than doubled in infants with 
severe BPD compared with infants with mild 
BPD. In a longitudinal study of motor and mental 
outcomes at 3 years of age, children with BPD of 
low socioeconomic status and minority race also 
appeared to have poorer cognitive outcomes [79]. In 
contrast, socioeconomic status does not appear to 
Table 5  Monitoring of home oxygen therapy for BPD [1, 17, 29]
Monitor for signs of hypoxia (e.g., cyanosis, lethargy, tachycardia, and irritability), poor weight gain, intercurrent illness
When possible, oxygen saturations should be evaluated while awake and asleep and during feedings
Wean slowly over several months and do not wean during intercurrent illness, as this is a time when oxygen requirements  
may increase
•	 Wean by small, incremental reductions in oxygen flow rates such as progressive halving of flow rates (e.g., from 0.5–0.25  
to 0.125–0.0625 L/min)
•	 Weaning should begin during daytime hours when the infant is awake and alert, for a period of 1–2 hours. 
High saturation targets > 97% are indicative of oxygen saturation, > 92% while asleep
•	 Observe infant for 2–4 weeks before next oxygen decrease
•	 Night-time weaning should begin after a minimum of 1 month of no daytime oxygen
Consider continuation or reinstatement of night-time oxygen if inadequate weight gain or new signs of hypoxia are evident
BPD bronchopulmonary dysplasia
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affect motor outcome positively or negatively [79]. 
These findings underscore the need for early 
diagnosis and intervention, and investigation 
into the potential role of BPD in higher rates of 
learning disabilities in VLBW/ELBW infants that 
may extend into the early school age period 
and beyond.
CONCLUSION
The pathophysiology and management of the 
VLBW/ELBW infant with BPD have evolved 
over the past four decades as improved NICU 
modalities have increased survival rates. 
However, the management of BPD and medically 
related problems, particularly during the first 
2 years of life, remains a continuing challenge for 
parents and healthcare providers. The following 
quote written by Dr. Mildred Stahlman, who is 
credited with the development of the modern 
NICU, appeared more than 20 years ago but 
is still relevant and applicable to current BPD 
management issues: “As sanguine as the future 
looks for [surfactant] therapy, it may leave us 
with more VLBW infants who survive where 
potential for normal growth and development 
is unknown, and whose very immature organ 
systems, besides the lung, are still susceptible to 
metabolic, neurologic, and other problems” [80]. 
There are many questions left to be answered by 
additional research on the effects of current and 
future treatment modalities on the long-term 
prognosis in these children.
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